What is Aurion Biotech?
Aurion Biotech is a clinical-stage biotechnology firm with operations in Seattle, Boston, and Tokyo. The company is dedicated to developing life-changing regenerative therapies aimed at restoring vision for millions of patients suffering from corneal edema secondary to endothelial dysfunction. Their lead candidate represents one of the first clinically validated cell therapies for corneal care. The proprietary process involves culturing healthy cells from a donor cornea, with a single donor's cells capable of treating over 100 recipient eyes. Clinical trials conducted in Japan have demonstrated significant and durable improvements in key corneal health metrics, including visual acuity, endothelial cell density, and central corneal thickness. This success positions Aurion Biotech for its upcoming clinical trials in the U.S.
How much funding has Aurion Biotech raised?
Aurion Biotech has raised a total of $120M across 1 funding round:
Other Financing Round
$120M
Other Financing Round (2022): $120M with participation from Visionary Ventures, Falcon Vision, Deerfield, Petrichor, and Flying High Partners, l3c
Key Investors in Aurion Biotech
Visionary Ventures
Visionary Ventures is a venture capital firm specializing in life sciences and ophthalmology startups, leveraging expert partnerships to identify promising companies and address unmet medical needs.
Deerfield
Deerfield Management is an investment firm dedicated to advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding and driving innovation.
Petrichor
Petrichor Capital Partners provides structured investments for the development and commercial growth of innovative biopharmaceuticals and medical technologies, focusing on customized structures and long-term strategies in healthcare.
What's next for Aurion Biotech?
The substantial enterprise-level funding and recent strategic investment provide Aurion Biotech with the necessary capital to advance its clinical development pipeline, particularly for its U.S. trials. This infusion of financing is expected to accelerate the company's path toward potential commercialization of its regenerative therapies for corneal edema. The company's focus on a patented, scalable cell-culturing process, where a single donor can treat multiple patients, suggests a strategy for efficient and widespread therapeutic delivery. Future growth will likely involve navigating regulatory pathways in the U.S. and potentially expanding its therapeutic applications to other vision-impairing conditions.
See full Aurion Biotech company page
